PLSH (Panacea Life Sciences Holdings) Debt-to-Equity: 0.06 (As of Sep. 2025)


What is Panacea Life Sciences Holdings Debt-to-Equity?

Panacea Life Sciences Holdings PLSH -28.57% Debt-to-Equity is 0.06 as of Sep. 2025. The stock has 10 warning signs investors should review. Among 812 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 80.42% on this metric.

Panacea Life Sciences Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.23 Mil. Panacea Life Sciences Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.00 Mil. Panacea Life Sciences Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2025 was $3.75 Mil. Panacea Life Sciences Holdings's debt to equity for the quarter that ended in Sep. 2025 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Panacea Life Sciences Holdings's Debt-to-Equity or its related term are showing as below:

PLSH' s Debt-to-Equity Range Over the Past 10 Years
Min: -41.18   Med: -1.59   Max: 7.61
Current: 0.06

During the past 4 years, the highest Debt-to-Equity Ratio of Panacea Life Sciences Holdings was 7.61. The lowest was -41.18. And the median was -1.59.

PLSH's Debt-to-Equity is ranked better than
80.42% of 812 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs PLSH: 0.06

Panacea Life Sciences Holdings  (OTCPK:PLSH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Panacea Life Sciences Holdings Debt-to-Equity Related Terms

Panacea Life Sciences Holdings Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Panacea Life Sciences Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Life Sciences Holdings Debt-to-Equity Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
3.41 2.11 -8.84 -2.61

Panacea Life Sciences Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.01 -1.83 -1.35 -1.14 0.06

PLSH vs SKYI, IMCC, CBDY: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Life Sciences Holdings Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's Debt-to-Equity falls into.


Panacea Life Sciences Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Panacea Life Sciences Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(14.818 + 6.827) / -8.291
=-2.61

Panacea Life Sciences Holdings's Debt to Equity Ratio for the quarter that ended in Sep. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.234 + 0) / 3.75
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.06 mean?
Panacea Life Sciences Holdings (PLSH) has a Debt-to-Equity of 0.06 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Panacea Life Sciences Holdings and its competitors. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #159 out of 812 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Panacea Life Sciences Holdings' Debt-to-Equity too high?
Panacea Life Sciences Holdings' current Debt-to-Equity is 0.06. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Panacea Life Sciences Holdings' value of 0.06 is 77.8% below this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #159 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Panacea Life Sciences Holdings' Debt-to-Equity compare to SKYI and IMCC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #159 out of 812 companies for Debt-to-Equity. This places Panacea Life Sciences Holdings in the top 20% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Panacea Life Sciences Holdings' value of 0.06 is 77.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current Debt-to-Equity of 0.06 is 77.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Debt-to-Equity is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Debt-to-Equity of 0.06. The current Debt-to-Equity is 0.06 and 77.8% below the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Debt-to-Equity is 0.06 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panacea Life Sciences Holdings Business Description

Address 5910 South University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.